Lenacapavir (GS-6207) sodium is a HIV-1 capsid inhibitor. Lenacapavir sodium shows anti-HIV activity with an EC50 of 100 pM in MT-4 cells. Lenacapavir sodium displays a mean EC50 of 50 pM (20-160 pM) against 23 HIV-1 clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs).

GSK-364735 sodium (S/GSK-364735 sodium) is the sodium salt form of GSK-364735 that inhibits 5-lipoxygenase with an IC50 value of 26 μM. 15(S)-HEDE is promising for research of inflammatory disease.

GSK-364735 potassium (S/GSK-364735 potassium) is the potassium salt form of GSK-364735, a local anesthetic that inhibits dopamine reuptake through the dopamine transporter.

Gardiquimod (hydrochloride) is an imidazoline TLR7/8 agonist. Gardiquimod (hydrochloride) inhibits HIV-1 infection of macrophages and activates peripheral blood mononuclear cells (PBMCs). Gardiquimod (hydrochloride) specifically activates TLR7 at concentrations below 10 μM.

CGP 57813 is a peptidomimetic inhibitor of HIV protease that can be encapsulated by nanoparticles composed of poly(D,L-lactic acid) (PLA) and pH-sensitive methacrylic acid copolymers and delivered into the body.

BRN3OMe is a potent HIV-1 reverse transcriptase inhibitor. BRN3OMe has the potential for the research of antiviral agent.

Amprenavir (Agenerase) is a HIV protease inhibitor(Ki=0.6 nM) used to treat HIV infection.

GPS491 (EC50 = 0.47 μM) suppresses expression of the HIV-1 structural protein Gag and alters HIV-1 RNA accumulation, decreasing the abundance of RNAs encoding the structural proteins while increasing levels of viral RNAs encoding the regulatory proteins.

Q308 is a small molecule that silences the latent HIV-1 provirus by inhibiting Tat-mediated gene transcription and selectively downregulates the expression levels of the facilitated chromatin transcription (FACT) complex.Q308 induced the preferential apoptosis in HIV-1 latently infected cells, Q308 may reduce the size of the viral reservoir.

Elunonavir is an azapeptide atazanavir analogs useful for treating HIV infections.

NBD-556 is small molecule mimetic of CD4, NBD-556 recognizes the HIV-1 envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding.

VTD227 is a small molecule Vpr-targeting HIV-1 inhibitor, directly binds to Vpr with Kd of 8.8 uM, inhibits HIV-1 replication in monocyte-derived macrophages (MDM) with IC50 of 0.78 uM.

TX-1918 (TX1918) is a specific inhibitor of HIV-1 capsid assembly taregting the C-terminal domain of HIV-1 capsid (CA CTD) with IC50 of 3.81 uM, inhibits viral replication (EC50=15.16 μM) and inhibits CA assembly in vitro.

SO-7g is a novel highly active HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI), exhibits moderate to excellent potency against wild-type HIV-1 with EC50 of 5.3 nM.

PAV-206 is a novel potent antiretroviral chemotype that inhibits HIV-1 replication with EC50 of 34 nM in HIV-1-infected MT-2 T cells, and 75 nM in HIV-1-infected peripheral blood mononuclear cells (PBMCs), inhibits HIV-1 replication by interfering with HI

JX-7 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with remarkable inhibitory activity against wild-type HIV-1 (EC50=5 nM) and numerous clinically observed variants in MT-4 cells.

iPAF1C (PAF1C inhibitor) is a first-in-class, specific inhibitor of polymerase-associated factor 1 complex (PAF1C), iPAF1C binds specifically to CTR9 and disrupts of PAF1-CTR9 interaction, enhances HIV-1 latency reversal.

GSK-878 (GSK878) is a highly potent, long-acting inhibitor targeting the HIV-1 capsid with picomolar potency against HIV-1 infection in vitro (EC50=39 pM).

GSK3839919 is a potent, allosteric HIV-1 integrase inhibitor (ALLINI).

GS-9770 is a potent, selective, non-peptidomimetic and orally active HIV protease inhibitor with Ki(app) value of 0.16 nM (recombinant HIV-1 PR).

Cyclotriazadisulfonamide (CADA) is a specific CD4-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way.

Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS,showed potent activity against COVID-19(SARS-COV-2) .

BRD-K98645985 is a class of 12-membered macrolactam and a BAF transcriptional repression inhibitor with an EC50 of ~2.37 µM. BRD-K98645985 binds ARID1A-specific BAF complexes, prevents nucleosomal positioning, and potently reverses HIV-1 latency, and without T cell activation or toxicity.

Emtricitabine is a nucleoside analogue which inhibits the reverse nucleoside transcriptase enzyme. Structurally this antiviral agent is similar to Lamivudine. This agent is effective at targeting HIV and HBV viruses since these viruses replicate in a reve

Fipravirimat is a potent HIV-1 inhibitor. Fipravirimat has the potential for HIV and AIDS research.

R-87366 is a water-soluble human immunodeficiency virus (HIV) protease inhibitor. R-87366 has potent inhibitory for HIV protease with a Ki value of 11 nM. R-87366 can be used for the research of anti-human immunodeficiency virus (HIV).

Carbovir triphosphate (CBV-TP) is a phosphorylated metabolite. Carbovir triphosphate can be used for the research of human immunodeficiency virus (HIV).

AZT triphosphate (3'-Azido-3'-deoxythymidine-5'-triphosphate) tetraammonium is an active triphosphate metabolite of Zidovudine (AZT). AZT triphosphate tetraammonium exhibits antiretroviral activity and inhibits replication of HIV. AZT triphosphate tetraammonium also inhibits the DNA polymerase of HBV. AZT triphosphate tetraammonium activates the mitochondria-mediated apoptosis pathway.

TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1, with EC50 and EC90 of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.

Rilpivirine(R 278474, TMC 278) is a type of anti-HIV medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI).